Brokerages Set Zura Bio Limited (NASDAQ:ZURA) PT at $16.75

Shares of Zura Bio Limited (NASDAQ:ZURA) have received a consensus recommendation of “Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.75.

Several research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday. HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research note on Monday, October 21st. Finally, Leerink Partners started coverage on shares of Zura Bio in a report on Monday. They set an “outperform” rating and a $15.00 price target on the stock.

Insider Buying and Selling at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Large investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC bought a new position in shares of Zura Bio during the 1st quarter worth about $1,157,000. Bank of New York Mellon Corp increased its stake in Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the period. Renaissance Technologies LLC increased its stake in Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,900 shares during the period. Great Point Partners LLC raised its holdings in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after acquiring an additional 876,000 shares during the period. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Price Performance

NASDAQ ZURA opened at $4.47 on Tuesday. The company has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $4.10. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Research analysts predict that Zura Bio will post -0.47 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.